Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression

1. Orlowski, R.Z.
2. Nagler, A.
3. Sonneveld, P.
4. Bladé, J.
5. Hajek, R.
6. Spencer, A.
7. San Miguel, J.
8. Robak, T.
9. Dmoszynska, A.
10. Horvath, N.
11. Spicka, I.
12. Sutherland, H.J.
13. Suvorov, A.N.
14. Zhuang, S.H.
15. Parekh, T.
16. Xiu, L.
17. Yuan, Z.
18. Rackoff, W.
19. Harousseau, J.-L.